

Niven Mehra

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4690887/publications.pdf>

Version: 2024-02-01

164
papers

4,617
citations

172443

29
h-index

123420

61
g-index

177
all docs

177
docs citations

177
times ranked

5889
citing authors

#	ARTICLE	IF	CITATIONS
1	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
2	Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients. <i>Annals of Oncology</i> , 2004, 15, 139-145.	1.2	222
3	Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1250-1264.	10.7	159
4	The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. <i>Nature</i> , 2019, 574, 127-131.	27.8	152
5	The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impact. <i>Nature Communications</i> , 2019, 10, 5251.	12.8	130
6	Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer. , 2022, 1, .		124
7	Lactate dehydrogenase: a marker of diminished antitumor immunity. <i>Oncolmmunology</i> , 2020, 9, 1731942.	4.6	107
8	Circulating Mitochondrial Nucleic Acids Have Prognostic Value for Survival in Patients with Advanced Prostate Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 421-426.	7.0	104
9	Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by Apheresis. <i>Clinical Cancer Research</i> , 2018, 24, 5635-5644.	7.0	88
10	Progenitor Marker CD133 mRNA Is Elevated in Peripheral Blood of Cancer Patients with Bone Metastases. <i>Clinical Cancer Research</i> , 2006, 12, 4859-4866.	7.0	84
11	Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>European Urology</i> , 2018, 74, 283-291.	1.9	82
12	Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naïve castration-resistant prostate cancer. , 2019, 7, 302.		72
13	Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations. <i>JAMA Network Open</i> , 2020, 3, e2021692.	5.9	70
14	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 724-731.	1.9	59
15	Proteome dynamics at broken replication forks reveal a distinct ATM-directed repair response suppressing DNA double-strand break ubiquitination. <i>Molecular Cell</i> , 2021, 81, 1084-1099.e6.	9.7	57
16	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , 2019, 30, v881-v882.	1.2	54
17	A phase I dose-escalation study of enzalutamide in combination with theÂAKT inhibitor AZD5363 (capiivasertib) in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2020, 31, 619-625.	1.2	54
18	Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C Î²-Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2007, 13, 4474-4481.	7.0	53

#	ARTICLE	IF	CITATIONS
19	Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. <i>Clinical Cancer Research</i> , 2021, 27, 3595-3601.	7.0	53
20	The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery. <i>Experimental Cell Research</i> , 2004, 301, 139-146.	2.6	52
21	Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. <i>Laboratory Investigation</i> , 2007, 87, 161-172.	3.7	45
22	Two-protein signature of novel serological markers apolipoprotein-A2 and serum amyloid alpha predicts prognosis in patients with metastatic renal cell cancer and improves the currently used prognostic survival models. <i>Annals of Oncology</i> , 2010, 21, 1472-1481.	1.2	44
23	Drug-drug interaction potential in men treated with enzalutamide: Mind the gap. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 122-129.	2.4	41
24	Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2020, 136, 16-24.	2.8	41
25	Tumor Genomic Testing for >4,000 Men with Metastatic Castration-resistant Prostate Cancer in the Phase III Trial PROfound (Olaparib). <i>Clinical Cancer Research</i> , 2022, 28, 1518-1530.	7.0	41
26	Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 423-430.	3.9	37
27	Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 460-469.	6.4	36
28	Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225Ac-PSMA-617 targeted alpha-radiation therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 729.e7-729.e16.	1.6	34
29	Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study. <i>Annals of Oncology</i> , 2019, 30, v328-v329.	1.2	32
30	Lutetium-177-PSMA-IT as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. <i>BMC Cancer</i> , 2020, 20, 884.	2.6	32
31	CCR 20th Anniversary Commentary: Paving the Way for Circulating Tumor Cells. <i>Clinical Cancer Research</i> , 2015, 21, 2883-2885.	7.0	31
32	TALAPRO-1: A phase II study of talazoparib (TALA) in men with DNA damage repair mutations (DDRmut) and metastatic castration-resistant prostate cancer (mCRPC) – First interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 119-119.	1.6	31
33	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 485-493.	1.9	30
34	Oligometastatic Prostate Cancer: Results of a Dutch Multidisciplinary Consensus Meeting. <i>European Urology Oncology</i> , 2020, 3, 231-238.	5.4	30
35	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq1 1 06784314 rgt /Ov	1.6	30
36	Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder. <i>Cancers</i> , 2020, 12, 2692.	3.7	29

#	ARTICLE	IF	CITATIONS
37	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 151-159.	5.4	28
38	Multicenter Comparison of Molecular Tumor Boards in The Netherlands: Definition, Composition, Methods, and Targeted Therapy Recommendations. <i>Oncologist</i> , 2021, 26, e1347-e1358.	3.7	28
39	Impact of DNA damage repair defects and aggressive variant features on response to carboplatin-based chemotherapy in metastatic castration-resistant prostate cancer. <i>International Journal of Cancer</i> , 2021, 148, 385-395.	5.1	28
40	Homologous Recombination Repair Deficiency and Implications for Tumor Immunogenicity. <i>Cancers</i> , 2021, 13, 2249.	3.7	28
41	Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA. <i>European Urology</i> , 2021, 80, 243-253.	1.9	28
42	Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study. <i>Clinical Chemistry</i> , 2020, 66, 842-851.	3.2	25
43	[⁶⁸ Ga]Ga-PSMA-11 PET imaging as a predictor for absorbed doses in organs at risk and small lesions in [¹⁷⁷ Lu]Lu-PSMA-617 treatment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1101-1112.	6.4	25
44	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. <i>Annals of Oncology</i> , 2017, 28, 90-95.	1.2	24
45	Circulating endothelial cells in cancer patients do not express tissue factor. <i>Cancer Letters</i> , 2004, 213, 241-248.	7.2	23
46	Comprehensive Molecular Characterization Reveals Genomic and Transcriptomic Subtypes of Metastatic Urothelial Carcinoma. <i>European Urology</i> , 2022, 81, 331-336.	1.9	23
47	First Experience With ¹⁷⁷ Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands. <i>Clinical Nuclear Medicine</i> , 2019, 44, 446-451.	1.3	22
48	Probing single-cell metabolism reveals prognostic value of highly metabolically active circulating stromal cells in prostate cancer. <i>Science Advances</i> , 2020, 6, .	10.3	22
49	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
50	Assessing the safety, tolerability and efficacy of PLGA-based immunomodulatory nanoparticles in patients with advanced NY-ESO-1-positive cancers: a first-in-human phase I open-label dose-escalation study protocol. <i>BMJ Open</i> , 2021, 11, e050725.	1.9	21
51	Molecular biomarkers to guide precision medicine in localized prostate cancer. <i>Expert Review of Molecular Diagnostics</i> , 2017, 17, 791-804.	3.1	20
52	Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative Analysis. <i>European Urology Oncology</i> , 2020, 3, 176-182.	5.4	19
53	Impact of DNA damage repair defects on response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 71-78.	3.9	19
54	²²³ Ra Therapy in Patients With Advanced Castration-Resistant Prostate Cancer With Bone Metastases. <i>Clinical Nuclear Medicine</i> , 2018, 43, 9-16.	1.3	18

#	ARTICLE	IF	CITATIONS
55	Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 79-87.	1.9	18
56	A Systematic Review and Meta-Analysis on the Predictive Value of Cell-Free DNA-Based Androgen Receptor Copy Number Gain in Patients With Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 714-729.	3.0	18
57	Neutrophil to Lymphocyte Ratio in Castration-Resistant Prostate Cancer Patients Treated With Daily Oral Corticosteroids. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 678-684.e1.	1.9	16
58	Early alkaline phosphatase dynamics as biomarker of survival in metastatic castration-resistant prostate cancer patients treated with radium-223. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 3325-3334.	6.4	15
59	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5566-5566.	1.6	15
60	Interrogating Metastatic Prostate Cancer Treatment Switch Decisions: A Multi-institutional Survey. <i>European Urology Focus</i> , 2018, 4, 235-244.	3.1	14
61	Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trial. <i>Trials</i> , 2021, 22, 768.	1.6	13
62	<i>CCR</i> 20th Anniversary Commentary: Circulating Tumor Cells in Prostate Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 4992-4995.	7.0	11
63	PROfound: Phase III study of olaparib versus enzalutamide or abiraterone for metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations. <i>Annals of Oncology</i> , 2019, 30, ix188-ix189.	1.2	11
64	68Ga-PSMA-Guided Bone Biopsies for Molecular Diagnostics in Patients with Metastatic Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2020, 61, 1607-1614.	5.0	11
65	Exploratory gene-by-gene analysis of olaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): PROfound.. <i>Journal of Clinical Oncology</i> , 2021, 39, 126-126.	1.6	11
66	<sc>ModraDoc006</sc>, an oral docetaxel formulation in combination with ritonavir (<sc>ModraDoc006</sc>/r), in metastatic castration-resistant prostate cancer patients: A phase Ib study. <i>Cancer Reports</i> , 2021, 4, e1367.	1.4	11
67	Clinical experience with PSMA-Actinium-225 (Ac-225) radioligand therapy (RLT) in end-stage metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 344-344.	1.6	11
68	Utilization of systemic treatment for metastatic bladder cancer in everyday practice: Results of a nation-wide population-based cohort study. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100266.	1.7	10
69	Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study. <i>European Journal of Cancer</i> , 2022, 170, 73-84.	2.8	10
70	A prospective phase I multicentre randomized cross-over pharmacokinetic study to determine the effect of food on abiraterone pharmacokinetics. <i>Cancer Chemotherapy and Pharmacology</i> , 2019, 84, 1179-1185.	2.3	9
71	TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 93-93.	1.6	9
72	Liquid biopsy reveals KLK3 mRNA as a prognostic marker for progression free survival in patients with metastatic castration-resistant prostate cancer undergoing first-line abiraterone acetate and prednisone treatment. <i>Molecular Oncology</i> , 2021, 15, 2453-2465.	4.6	9

#	ARTICLE	IF	CITATIONS
73	Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types. <i>Clinical Cancer Research</i> , 2021, 27, 6106-6114.	7.0	9
74	What have we learned from exceptional tumour responses?. <i>Current Opinion in Oncology</i> , 2015, 27, 267-275.	2.4	8
75	68Ga-PSMA-PET/CT and Diffusion MRI Targeting for Cone-Beam CT-Guided Bone Biopsies of Castration-Resistant Prostate Cancer Patients. <i>CardioVascular and Interventional Radiology</i> , 2020, 43, 147-154.	2.0	8
76	M1a prostate cancer: Results of a Dutch multidisciplinary consensus meeting. <i>BJUI Compass</i> , 2021, 2, 159-168.	1.3	8
77	The effects of new life-prolonging drugs for metastatic castration-resistant prostate cancer (mCRPC) patients in a real-world population. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 871-879.	3.9	8
78	Myeloid-derived suppressor cells (MDSCs) in metastatic castration-resistant prostate cancer (CRPC) patients (PTS). <i>Annals of Oncology</i> , 2016, 27, vi257.	1.2	7
79	Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer. <i>Value in Health</i> , 2017, 20, 1411-1419.	0.3	7
80	A clinically relevant decrease in abiraterone exposure associated with carbamazepine use in a patient with castration-resistant metastatic prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2018, 84, 1064-1067.	2.4	7
81	The Combination of Enzalutamide and Opioids: A Painful Pitfall?. <i>European Urology</i> , 2019, 75, 351-352.	1.9	7
82	Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer models. <i>Cancer Gene Therapy</i> , 2022, 29, 793-802.	4.6	7
83	Real-world Outcomes of Sequential Androgen-receptor Targeting Therapies with or Without Interposed Life-prolonging Drugs in Metastatic Castration-resistant Prostate Cancer: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Oncology</i> , 2021, 4, 618-627.	5.4	6
84	A tipping point in cancer-immune dynamics leads to divergent immunotherapy responses and hampers biomarker discovery. , 2021, 9, e002032.		6
85	Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 667658.	2.8	6
86	Overall Survival of Patients Receiving Cisplatin or Carboplatin for Primary Metastatic Urothelial Carcinoma of the Bladder: A Contemporary Dutch Nationwide Cohort Study. <i>European Urology Focus</i> , 2022, 8, 995-1002.	3.1	6
87	PROfound: Efficacy of olaparib (ola) by prior taxane use in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.. <i>Journal of Clinical Oncology</i> , 2020, 38, 134-134.	1.6	6
88	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
89	Responsiveness to Immune Checkpoint Inhibitors Is Associated With a Peripheral Blood T-Cell Signature in Metastatic Castration-Resistant Prostate Cancer. <i>JCO Precision Oncology</i> , 2020, 4, 1374-1385.	3.0	6
90	Now the dust has settled over immune checkpoint blockade in metastatic prostate cancer. <i>Annals of Oncology</i> , 2018, 29, 1620-1622.	1.2	5

#	ARTICLE	IF	CITATIONS
91	Future therapeutic strategies for metastatic prostate cancer. <i>Tijdschrift Voor Urologie</i> , 2019, 9, 117-130.	0.1	5
92	Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e946-e956.	1.9	5
93	The impact of patient characteristics on enzalutamide pharmacokinetics and how this relates to treatment toxicity and efficacy in metastatic prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 753-760.	2.3	5
94	Prospective bladder cancer infrastructure for experimental and observational research on bladder cancer: study protocol for the "trials within cohorts"™ study ProBCI. <i>BMJ Open</i> , 2021, 11, e047256.	1.9	5
95	The effect of chemotherapy on the exposure-response relation of abiraterone in metastatic castration-resistant prostate cancer. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 1170-1178.	2.4	5
96	Plasma BRAF Mutation Detection for the Diagnostic and Monitoring Trajectory of Patients with LDH-High Stage IV Melanoma. <i>Cancers</i> , 2021, 13, 3913.	3.7	5
97	Immunological and genomic correlates of response to anti-PD1 checkpoint therapy in mismatch proficient and deficient patients with metastasized castration resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 248-248.	1.6	5
98	Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer. <i>BJU International</i> , 2021, , .	2.5	5
99	Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer. <i>Frontiers in Immunology</i> , 2021, 12, 802877.	4.8	5
100	Evidence or Prejudice? Critical Re-Analysis of Randomized Controlled Trials Comparing Overall Survival After Cisplatin Versus Carboplatin-Based Regimens in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e346-e352.	1.9	5
101	Impact of molecular tumour board discussion on targeted therapy allocation in advanced prostate cancer. <i>British Journal of Cancer</i> , 2022, 126, 907-916.	6.4	5
102	RNA Biomarkers as a Response Measure for Survival in Patients with Metastatic Castration-Resistant Prostate Cancer. <i>Cancers</i> , 2021, 13, 6279.	3.7	5
103	Health-related quality of life, psychological distress, and fatigue in metastatic castration-resistant prostate cancer patients treated with radium-223 therapy. <i>Prostate Cancer and Prostatic Diseases</i> , 2023, 26, 142-150.	3.9	5
104	Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2020, 18, e233-e253.	1.9	4
105	High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 536700.	2.8	4
106	Prior PSMA PET-CT Imaging and Hounsfield Unit Impact on Tumor Yield and Success of Molecular Analyses from Bone Biopsies in Metastatic Prostate Cancer. <i>Cancers</i> , 2020, 12, 3756.	3.7	4
107	High-Intensity Care in the End-of-Life Phase of Castration-Resistant Prostate Cancer Patients: Results from the Dutch CAPRI-Registry. <i>Journal of Palliative Medicine</i> , 2021, 24, 1789-1797.	1.1	4
108	Lutetium-177-PSMA-617 in low-volume hormone sensitive metastatic prostate cancer: a prospective study. , 2020, 59, .		4

#	ARTICLE	IF	CITATIONS
109	In-depth assessment of metastatic prostate cancer with high tumour mutational burden. <i>Annals of Oncology</i> , 2018, 29, viii274.	1.2	3
110	LDH Isotyping for Checkpoint Inhibitor Response Prediction in Patients with Metastatic Melanoma. <i>Immuno</i> , 2021, 1, 67-77.	1.5	3
111	Association between PSA declines at 4 weeks and OS in patients treated with abiraterone acetate (AA) for metastatic castration resistant prostate cancer (mCRPC) after docetaxel.. <i>Journal of Clinical Oncology</i> , 2015, 33, 215-215.	1.6	3
112	Phase 1/2 trial of cabazitaxel with abiraterone acetate in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone acetate: Phase 2 results.. <i>Journal of Clinical Oncology</i> , 2015, 33, 268-268.	1.6	3
113	Association of plasma cell-free DNA concentration [cfDNA] with outcome from taxane therapy (TT) for castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5014-5014.	1.6	3
114	High neutrophil-to-lymphocyte ratio (NLR), myeloid-derived suppressor cells (MDSCs) and resistance to corticosteroid therapy (CST) in castration-resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5076-5076.	1.6	3
115	A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 in patients with mCRPC.. <i>Journal of Clinical Oncology</i> , 2017, 35, 135-135.	1.6	3
116	Overall survival using radium-223 (Ra223) in metastatic castrate-resistant prostate cancer (mCRPC) patients with and without DNA damage repair (DDR) defects.. <i>Journal of Clinical Oncology</i> , 2020, 38, 121-121.	1.6	3
117	ModraDoc006, an oral docetaxel formulation in combination with ritonavir (ModraDoc006/r), in metastasized castration-resistant prostate cancer (mCRPC): A multicenter phase I study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 79-79.	1.6	3
118	Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands. <i>Clinical Genitourinary Cancer</i> , 2022, 20, 43-52.	1.9	3
119	Homologous recombination repair deficient prostate cancer represents an immunologically distinct subtype. <i>Oncolmmunology</i> , 2022, 11, .	4.6	3
120	Natural dendritic cell vaccinations generate immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2019, 30, v480.	1.2	2
121	Whole Blood Transcriptome Profiling Identifies DNA Replication and Cell Cycle Regulation as Early Marker of Response to Anti-PD-1 in Patients with Urothelial Cancer. <i>Cancers</i> , 2021, 13, 4660.	3.7	2
122	Clinical characteristics of metastatic castration-resistant prostate cancer (mCRPC) patients with DNA repair (DNAr) defects.. <i>Journal of Clinical Oncology</i> , 2016, 34, 5028-5028.	1.6	2
123	Correlates of response to anti-PD-1 immune checkpoint blockade (ICB) in mismatch repair proficient (MMRp) and deficient (MMRd) patients (pts) with metastatic castration resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 5036-5036.	1.6	2
124	Myeloid and plasmacytoid dendritic cell vaccinations for castration-resistant prostate cancer patients.. <i>Journal of Clinical Oncology</i> , 2018, 36, 219-219.	1.6	2
125	Cell-free DNA as a biomarker for taxane treatment in advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, 5070-5070.	1.6	2
126	TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)â€™Exploration of germline DDR alteration landscape and potential associations with antitumor activity.. <i>Journal of Clinical Oncology</i> , 2022, 40, 157-157.	1.6	2

#	ARTICLE	IF	CITATIONS
127	An Update to the Pilot Study of 177Lu-PSMA in Low Volume Hormone-Sensitive Prostate Cancer. <i>Frontiers in Nuclear Medicine</i> , 2022, 2, .	1.2	2
128	On-treatment plasma ctDNA fraction and treatment outcomes in metastatic castration-resistant prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 5051-5051.	1.6	2
129	2558 Impact of PTEN protein loss on response to docetaxel and overall survival (OS) in metastatic castration resistant prostate cancer (mCRPC) patients. <i>European Journal of Cancer</i> , 2015, 51, S496.	2.8	1
130	Platinum-based therapy in men with metastatic castration resistant prostate (mCRPC) with or without DNA repair defects: A multicentre retrospective analysis. <i>Annals of Oncology</i> , 2018, 29, viii282.	1.2	1
131	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. <i>European Urology Focus</i> , 2021, 7, 788-796.	3.1	1
132	Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5047-5047.	1.6	1
133	Consensus statement on circulating biomarkers for advanced prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 299-299.	1.6	1
134	Olaparib monotherapy in pretreated patients with BRCA1/2 alterations: Results of a DRUP trial cohort.. <i>Journal of Clinical Oncology</i> , 2020, 38, 3633-3633.	1.6	1
135	Intratumoral T cell depletion following neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer is associated with poor clinical outcome. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	4.2	1
136	Identification of two new serum protein profiles for renal cell carcinoma. <i>Oncology Reports</i> , 2009, , .	2.6	0
137	2578 Neutrophil-to-lymphocyte ratio (NLR) in relation to outcome of castration-resistant prostate cancer (CRPC) patients treated with corticosteroids (CS). <i>European Journal of Cancer</i> , 2015, 51, S504.	2.8	0
138	2579 Evaluation of clinical decision-making and the use of circulating tumor cells (CTCs) by physicians treating castration-resistant prostate cancer (CRPC). <i>European Journal of Cancer</i> , 2015, 51, S504.	2.8	0
139	Abiraterone for the Treatment of mCRPC. , 2016, , 125-155.		0
140	Physiciansâ€™ Behavior Influences the Health and Economic Impact of Applying Circulating Tumor Cells as Response Marker in Metastatic Castration-Resistant Prostate Cancer. <i>Value in Health</i> , 2016, 19, A765-A766.	0.3	0
141	PCN388 - PATIENT REPORTED OUTCOMES IN THE CASTRATION RESISTANT PROSTATE CANCER REGISTRY (PRO-CAPRI) IN THE NETHERLANDS. <i>Value in Health</i> , 2018, 21, S80.	0.3	0
142	Symptomatic skeletal related events (SSE) and SSE-free-survival in real world castration-resistant prostate cancer (CRPC) patients: Results from CAPRI. <i>Annals of Oncology</i> , 2018, 29, viii282-viii283.	1.2	0
143	Cabazitaxel treatment in metastatic castration-resistant prostate cancer (mCRPC) clinical trials compared to usual care in CAPRI: An observational study in the Netherlands. <i>Annals of Oncology</i> , 2018, 29, viii283-viii284.	1.2	0
144	Reply to Vincenza Conteduca, Giorgia Gurioli, and Ugo De Giorgi's Letter to the Editor re: Niven Mehra, David Dolling, Semini Sumanasuriya, et al. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). <i>Eur Urol</i> . In press. https://doi.org/10.1016/j.eururo.2018.02.013 . <i>European Urology</i> , 2018, 74, e69-e70.	1.9	0

#	ARTICLE	IF	CITATIONS
145	Response to comment on "Impact of DNA damage repair defects on response to radium-223 and overall survival in metastatic castration-resistant prostate cancer" European Journal of Cancer, 2021, 144, 395-396.	2.8	0
146	Triple AiM1: A prospective observational study of treatment options in men with metastatic hormone sensitive prostate cancer. European Urology, 2021, 79, S1225.	1.9	0
147	Abstract 2190: Integrative genomic and transcriptomic characterization of metastatic urothelial carcinoma. , 2021, , .		0
148	Abstract CT027: TALAPRO-1 final data: Talazoparib (TALA) monotherapy in men with DNA damage response alterations (DDRalt) and metastatic castration-resistant prostate cancer (mCRPC): Exploration of DDRalt germline/somatic origin and zygosity. , 2021, , .		0
149	Use of serum proteins identified by proteomics to predict prognosis in patients with metastatic renal cell cancer (mRCC) and comparison to the currently used MSKCC survival model. Journal of Clinical Oncology, 2009, 27, 11078-11078.	1.6	0
150	PSA levels after dexamethasone withdrawal (DW) in castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2016, 34, 278-278.	1.6	0
151	Interrogating metastatic prostate cancer treatment switch decisions.. Journal of Clinical Oncology, 2016, 34, 296-296.	1.6	0
152	Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis.. Journal of Clinical Oncology, 2016, 34, 280-280.	1.6	0
153	Cabazitaxel for the Treatment of Prostate Cancer. , 2016, , 187-214.		0
154	Circulating tumor cell (CTC) rise and outcome in patients with metastatic castration-resistant prostate cancer (mCRPC) with low baseline CTC counts.. Journal of Clinical Oncology, 2016, 34, 5042-5042.	1.6	0
155	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. Journal of Clinical Oncology, 2016, 34, 5043-5043.	1.6	0
156	Abstract 4976: Monitoring CHD1 during prostate cancer progression. , 2016, , .		0
157	The complete genomic landscape of metastatic prostate cancer pinpoints clinically targetable subgroups.. Journal of Clinical Oncology, 2018, 36, 5014-5014.	1.6	0
158	Early changes in PSA and association with outcomes in mCRPC patients.. Journal of Clinical Oncology, 2018, 36, 5063-5063.	1.6	0
159	Abstract A051: Liquid biopsy by apheresis: Molecular characterization of circulating tumor cells and their organoid culture reflects inpatient heterogeneity and clonal evolution. , 2018, , .		0
160	Does a food intervention makes abiraterone treatment affordable?. Journal of Clinical Oncology, 2019, 37, e16523-e16523.	1.6	0
161	Abstract 1413: Exploring the prognostic value of microRNAs and drug exposure in patients with metastatic castration resistant prostate cancer treated with abiraterone: a prospective observational study. , 2020, , .		0
162	First results of the PROMPT trial: Precision oncology allocation in patients with early castration-resistant prostate cancer following routine molecular profiling.. Journal of Clinical Oncology, 2022, 40, 40-40.	1.6	0

#	ARTICLE	IF	CITATIONS
163	Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate Cancer. <i>Drugs - Real World Outcomes</i> , 2022, , 1.	1.6	0
164	Abstract CT031: TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with tumor DNA damage response alterations (DDRm)â€“ Exploration of genomic loss of heterozygosity (gLOH) and potential associations with antitumor activity. <i>Cancer Research</i> , 2022, 82, CT031-CT031.	0.9	0